5-ethoxy-2-methyladamantan-2-ol | 952426-88-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5-ethoxy-2-methyladamantan-2-ol
• CAS: 952426-88-9
• 化学式: C₁₃H₂₂O₂
• 分子量: 210.316
• InChiKey: KGROCOBVFIWPQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Gopalan Balasubramanian

  公开号：US20100160302A1

  公开（公告）日：2010-06-24

  The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined. The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.

  本发明涉及由式(I)所代表的新化合物，其中R，R1，R2，R3，X，Y，m，n如定义所示。本发明涉及通式I化合物及其衍生物、类似物、互变异构体、立体异构体、对映异构体、生物等构体、多晶型、其药学上可接受的盐和包含它们的药学上可接受的组合物，这些化合物主要是二肽基肽酶IV抑制剂。本发明还涉及制备式(I)的新化合物的过程，以及它们在治疗II型糖尿病及其并发症以及治疗血脂异常、高胆固醇血症、肥胖症和高血糖方面的应用。
• US7985759B2
  申请人：——

  公开号：US7985759B2

  公开（公告）日：2011-07-26
• [EN] NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE IV ET PROCÉDÉS POUR LA PRÉPARATION DE CEUX-CI ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CEUX-CI
  申请人：MATRIX LAB LTD

  公开号：WO2007113634A1

  公开（公告）日：2007-10-11

  [EN] The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia.
  [FR] La présente invention concerne de nouveaux composés représentés par la formule (I), dans laquelle R, R1, R2, R3, X, Y, m et n sont tels que définis dans la présente. La présente invention concerne les composés de formule générale (I), leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs diastéréoisomères, leurs bioisostères, leurs polymorphes, leurs sels acceptables du point de vue pharmaceutique et des compositions acceptables du point de vue pharmaceutique contenant ceux-ci, qui sont principalement des inhibiteurs de la dipeptidyl peptidase IV. La présente invention concerne également les procédés pour la préparation des nouveaux composés de formule (I) et l'utilisation de ceux-ci dans le traitement du diabète de type II et de complications diabétiques associées et également pour traiter la dyslipidémie, l'hypercholestérolémie, l'obésité et l'hyperglycémie.